Altamira Therapeutics Ltd.
CYTOF
$0.07
$0.0046.06%
OTC PK
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | 58.70K | 115.70K | -360.90K | -836.40K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 58.70K | 115.70K | -360.90K | -836.40K |
| Cost of Revenue | -- | -- | -- | -- | 127.50K |
| Gross Profit | -- | -- | -- | -- | -602.80K |
| SG&A Expenses | 1.99M | 2.12M | 2.25M | 490.40K | 1.42M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -34.20K | -55.80K | -77.40K | 413.60K | 181.50K |
| Total Operating Expenses | 3.92M | 3.79M | 3.66M | -2.28M | 459.80K |
| Operating Income | -3.92M | -3.79M | -3.66M | 2.45M | -761.50K |
| Income Before Tax | -4.34M | -4.43M | -4.52M | -5.41M | -15.32M |
| Income Tax Expenses | -- | -- | -- | 21.00K | 39.60K |
| Earnings from Continuing Operations | -4.34 | -4.43 | -4.52 | -5.43 | -15.36 |
| Earnings from Discontinued Operations | -- | -710.40K | -1.42M | -1.42M | -1.42M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.34M | -5.14M | -5.94M | -15.03M | -24.96M |
| EBIT | -3.92M | -3.79M | -3.66M | 2.45M | -761.50K |
| EBITDA | -- | -1.83M | -3.66M | 2.50M | -713.00K |
| EPS Basic | -30.42 | -43.52 | -56.63 | -220.81 | -413.01 |
| Normalized Basic EPS | -1.32 | -7.44 | -13.56 | 71.73 | 35.76 |
| EPS Diluted | -30.42 | -43.52 | -56.63 | -220.81 | -413.01 |
| Normalized Diluted EPS | -1.32 | -7.44 | -13.56 | 71.73 | 35.76 |
| Average Basic Shares Outstanding | 4.61M | 2.76M | 911.30K | 465.50K | 508.80K |
| Average Diluted Shares Outstanding | 4.82M | 2.97M | 1.12M | 675.50K | 508.80K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |